Featured Press Releases

SK bioscience Receives WHO Prequalification for Typhoid Conjugate Vaccine

SK bioscience Receives WHO Prequalification for Typhoid Conjugate Vaccine

ISCT becomes the first cell and gene therapy organization to achieve ANAB accreditation for its workforce development program

ISCT becomes the first cell and gene therapy organization to achieve ANAB accreditation for its workforce development program

  • 01 Oct 2024

The ISCT Institute of Training & Development, a division of the International Society for Cell and...

Moleculin

Moleculin's AML treatment gets EMA's Orphan Drug Designation

Ouro Medicines launches to transform treatment for immune-mediated diseases with innovative therapies

Ouro Medicines launches to transform treatment for immune-mediated diseases with innovative therapies

PANTHERx® Rare is selected by Calliditas Therapeutics as the specialty pharmacy for TARPEYO®.

PANTHERx® Rare is selected by Calliditas Therapeutics as the specialty pharmacy for TARPEYO®.

MM+M honors Petauri

MM+M honors Petauri's Nicole Lodowski as a 2025 40 Under 40 awardee

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

  • Spruce Biosciences, Inc.
  • 18 Aug 2025
Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • SystImmune, Inc.
  • 18 Aug 2025
New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

  • Genexa
  • 15 Aug 2025
Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

  • Daewoong Therapeutics Inc
  • 13 Aug 2025
Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

  • Abcentra
  • 12 Aug 2025
Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • Viatris Inc.
  • 11 Aug 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.